{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:43:16Z","timestamp":1787766196330,"version":"build-2784847793"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nutritional status is a major prognostic factor for breathing and the survival of patients with cystic fibrosis (CF). Since 2012, the development of CFTR modulators has considerably transformed the outcome of this disease. Indeed, both lung function and body mass index are improved by CFTR modulators, such as Lumacaftor\/Ivacaftor. However, few data exist regarding the outcome of nutritional intakes under Lumacaftor\/Ivacaftor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective single-center study in children with CF treated with Lumacaftor\/Ivacaftor to evaluate their nutritional intake before and after treatment<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-four children were included in this study, with a median age of 12.4 years [11.9; 14.7]. There was no significant improvement in weight, height or BMI. Patients' total energy intake was not significantly changed with Lumacaftor\/Ivacaftor, while carbohydrate intakes decreased significantly. We found that blood levels of vitamin E and Selenium were significantly increased under Lumacaftor\/Ivacaftor, without a significant increase in supplementation. In patients with a BMI Z-score\u2009&amp;lt;\u20090 at treatment initiation, there was a significant improvement in weight and BMI Z-score, while TEI and carbohydrate intakes were significantly lower.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We showed that treatment with Lumacaftor\/Ivacaftor improved the nutritional status of patients without necessarily being associated with an increase in nutritional intake. Although these data need to be confirmed in larger cohorts, they support the hypothesis that weight gain under modulators is multifactorial, and may be related to a decrease in energy expenditure or an improvement in absorption.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1130790","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T09:13:24Z","timestamp":1680081204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Nutritional impact of CFTR modulators in children with cystic fibrosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Margaux","family":"Gaschignard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lussac-Sorton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Gallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haude","family":"Clouzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Nouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Delhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Tetard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Enaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1055\/s-0039-1696726","article-title":"Growth and nutrition in cystic fibrosis","volume":"40","author":"Brownell","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/01.mpg.0000178439.64675.8d","article-title":"Gastrointestinal outcomes and confounders in cystic fibrosis","volume":"41","author":"Borowitz","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1569-1993(02)00032-2","article-title":"Nutrition in patients with cystic fibrosis: a European consensus","volume":"1","author":"Sinaasappel","year":"2002","journal-title":"J Cyst Fibros"},{"key":"B5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in cystic fibrosis","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr Clin Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jcf.2017.01.010","article-title":"Macronutrient intake in preschoolers with cystic fibrosis and the relationship between macronutrients and growth","volume":"16","author":"Filigno","year":"2017","journal-title":"J Cyst Fibros"},{"key":"B8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","article-title":"A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis","volume":"9","author":"Habib","year":"2019","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub3","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/MPG.0000000000002864","article-title":"Reduced intestinal inflammation with lumacaftor\/ivacaftor in adolescents with cystic fibrosis","volume":"71","author":"T\u00e9tard","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jcf.2021.08.032","article-title":"Restoration of exocrine pancreatic function in child with lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"21","author":"Crowley","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B15","volume-title":"Human energy requirements","year":"2004"},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jcf.2018.06.004","article-title":"Italian And north American dietary intake after ivacaftor treatment for cystic fibrosis gating mutations","volume":"18","author":"Sainath","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jcf.2015.01.006","article-title":"Cystic\u00a0fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation","volume":"14","author":"Bodewes","year":"2015","journal-title":"J Cyst Fibros"},{"key":"B18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0006-291x(03)00811-8","article-title":"Vitamin E and drug metabolism","volume":"305","author":"Brigelius-Floh\u00e9","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MPG.0000000000000683","article-title":"Intestinal inflammation and impact on growth in children with cystic fibrosis","volume":"60","author":"Dhaliwal","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.prrv.2020.04.003","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","volume":"35","author":"Nichols","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jcf.2020.06.015","article-title":"Lumacaftor\/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis","volume":"20","author":"Gelzo","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.freeradbiomed.2008.12.007","article-title":"Vitamin E: the shrew waiting to be tamed","volume":"46","author":"Brigelius-Floh\u00e9","year":"2009","journal-title":"Free Radic Biol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MPG.0b013e31804069e5","article-title":"Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis","volume":"45","author":"Hakim","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of lumacaftor\u2013ivacaftor on lung clearance Index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1007\/s12011-020-02444-w","article-title":"Zinc and selenium in inflammatory bowel disease: trace elements with key roles?","volume":"199","author":"Vaghari-Tabari","year":"2021","journal-title":"Biol Trace Elem Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/antiox10030483","article-title":"CFTR Modulator therapy with lumacaftor\/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis","volume":"10","author":"Sommerburg","year":"2021","journal-title":"Antioxidants"},{"key":"B28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcf.2019.12.015","article-title":"Clinical effect of lumacaftor\/ivacaftor in F508del homozygous CF patients with FEV1 \u2265 90% predicted at baseline","volume":"19","author":"Aalbers","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jcf.2017.09.012","article-title":"Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR","volume":"17","author":"Taylor-Cousar","year":"2018","journal-title":"J Cyst Fibros"},{"key":"B31","doi-asserted-by":"publisher","first-page":"744705","DOI":"10.3389\/fped.2021.744705","article-title":"Long-term outcomes in real life of lumacaftor-ivacaftor treatment in adolescents with cystic fibrosis","volume":"9","author":"Bui","year":"2021","journal-title":"Front Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1130790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T09:13:28Z","timestamp":1680081208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1130790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":32,"alternative-id":["10.3389\/fped.2023.1130790"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1130790","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"article-number":"1130790"}}